185 related articles for article (PubMed ID: 24900771)
1. Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor.
Fisher N; Hilton-Bolt T; Edwards MG; Haxton KJ; McKenzie M; Allin SM; Richardson A
ACS Med Chem Lett; 2014 Jan; 5(1):34-9. PubMed ID: 24900771
[TBL] [Abstract][Full Text] [Related]
2. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.
Ferry G; Moulharat N; Pradère JP; Desos P; Try A; Genton A; Giganti A; Beucher-Gaudin M; Lonchampt M; Bertrand M; Saulnier-Blache JS; Tucker GC; Cordi A; Boutin JA
J Pharmacol Exp Ther; 2008 Dec; 327(3):809-19. PubMed ID: 18755937
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Activity of a Novel Autotaxin Inhibitor-Icodextrin Conjugate.
Fisher N; Edwards MG; Hemming R; Allin SM; Wallis JD; Bulman Page PC; Mckenzie MJ; Jones SM; Elsegood MRJ; King-Underwood J; Richardson A
J Med Chem; 2018 Sep; 61(17):7942-7951. PubMed ID: 30059212
[TBL] [Abstract][Full Text] [Related]
4. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
[TBL] [Abstract][Full Text] [Related]
5. ATX/LPA axis regulates FAK activation, cell proliferation, apoptosis, and motility in human pancreatic cancer cells.
Liao Y; Liu L; Yang J; Shi Z
In Vitro Cell Dev Biol Anim; 2022 Apr; 58(4):307-315. PubMed ID: 35426066
[TBL] [Abstract][Full Text] [Related]
6. Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin.
Jiang G; Madan D; Prestwich GD
Bioorg Med Chem Lett; 2011 Sep; 21(17):5098-101. PubMed ID: 21489790
[TBL] [Abstract][Full Text] [Related]
7. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.
Thirunavukkarasu K; Tan B; Swearingen CA; Rocha G; Bui HH; McCann DJ; Jones SB; Norman BH; Pfeifer LA; Saha JK
J Pharmacol Exp Ther; 2016 Oct; 359(1):207-14. PubMed ID: 27516465
[TBL] [Abstract][Full Text] [Related]
9. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
10. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.
Saga H; Ohhata A; Hayashi A; Katoh M; Maeda T; Mizuno H; Takada Y; Komichi Y; Ota H; Matsumura N; Shibaya M; Sugiyama T; Nakade S; Kishikawa K
PLoS One; 2014; 9(4):e93230. PubMed ID: 24747415
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
[TBL] [Abstract][Full Text] [Related]
15. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
[TBL] [Abstract][Full Text] [Related]
18. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
[TBL] [Abstract][Full Text] [Related]
19. The atherogenic actions of LPC on vascular smooth muscle cells and its LPA receptor mediated mechanism.
Bao L; Qi J; Wang YW; Xi Q; Tserennadmid T; Zhao PF; Qi J; Damirin A
Biochem Biophys Res Commun; 2018 Sep; 503(3):1911-1918. PubMed ID: 30064908
[TBL] [Abstract][Full Text] [Related]
20. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells.
Vidot S; Witham J; Agarwal R; Greenhough S; Bamrah HS; Tigyi GJ; Kaye SB; Richardson A
Cell Signal; 2010 Jun; 22(6):926-35. PubMed ID: 20100569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]